Anthem Blue Cross

Clinical Cumulative Morphine Equivalent Dosing Point of Sale Edit effective January 1, 2017

Beginning January 1, 2017 most Anthem Blue Cross Medicare Advantage plans will implement a cumulative morphine equivalent (MEq) dosing edit at the point of sale. This MEq dosing edit will identify members taking a cumulative dose that exceeds the daily dose that Anthem sets. This is a patient safety edit intended to reduce the risk from high dose opioid use. There is a higher risk for overdose when exceeding the set MEq dosing limit. The claim(s) will reject at the point of sale and require a prior authorization review if the cumulative dosing is over the set daily limit. Certain members may be excluded from the edit, such as members with cancer. The edit supports the CMS guidance mandating that Medicare plans implement a cumulative dosing edit. Anthem anticipates that this edit will impact a fairly high number of claims.

60509WPPENMUB 06/09/2016

Anthem Blue Cross is the trade name of Blue Cross of California: Independent licensee of the Blue Cross Association. ® ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross names and symbols are registered marks of the Blue Cross Association.